In the acute setting of myocardial infarction, it was recently demonstrated that prior use of SGLT-2 inhibitors among the affected subjects resulted in significantly lower rates of atrial fibrillation, ventricular tachycardia and ventricular fibrillation, while SGLT-2 inhibitor use was associated with a significant reduction in the odds for new-onset arrhythmia during hospitalization by 65% [53]. The gene discussed is SLC5A2; the disease is myocardial infarction.